The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer
- PMID: 20097087
- DOI: 10.1016/j.critrevonc.2010.01.002
The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer
Abstract
Objective: To investigate the influences of age and co-morbidities on the use of adjuvant chemotherapy and trastuzumab in patients with HER2-positive early breast cancer.
Methods: Thirty surgeons and 101 oncologists reviewed the profiles of 16 hypothetical patients which included details of age, tumour size/grade, nodal/ER status, and co-morbidities. Respondents viewed different patient profiles. Oncologists were asked how likely they would be to prescribe chemotherapy ± trastuzumab. Surgeons were asked whether they would refer to an oncologist.
Results: Oncologists' treatment decisions were most affected by age and co-morbidities: 81% would prescribe chemotherapy for a high-risk patient aged 68 years, but only 47% for an otherwise identical patient aged 73 years. The majority of surgeons (84%) would still refer older patients.
Conclusions: National variation in the use of adjuvant chemotherapy in women aged ≥70 years with high-risk breast cancer is substantial. Practice audits or clinical trials addressing the outcomes of systemic adjuvant therapy are needed for this ever-increasing population of patients.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous